Related Experiment Videos
Renal effect of SB 7505: a double-blind study
European Journal of Clinical Pharmacology
|February 1, 1981
Summary
SB 7505 significantly increased urine output and electrolyte excretion in patients without organ failure. This study found no adverse effects on heart rate or blood pressure during the five-day treatment period.
Area of Science:
- Pharmacology
- Nephrology
- Cardiovascular Physiology
Background:
- Understanding the physiological effects of novel drug compounds is crucial.
- Assessing potential impacts on renal function and cardiovascular stability is a key aspect of drug development.
Purpose of the Study:
- To evaluate the effects of SB 7505 on renal function and cardiovascular parameters.
- To determine the safety and efficacy of SB 7505 in a human cohort.
Main Methods:
- A randomized, placebo-controlled study involving two groups of 20 patients.
- Oral administration of SB 7505 (100 mg/day) or placebo for five days.
- Monitoring of heart rate, blood pressure, urine output, electrolyte excretion (Na, K, Cl), and creatinine clearance.
Main Results:
- SB 7505 treatment led to a significant increase in urine output.
- Significant increases in sodium, potassium, and chloride excretion were observed.
- Creatinine clearance was also significantly elevated in the SB 7505 group.
- No significant changes in heart rate or blood pressure were detected.
Conclusions:
- SB 7505 demonstrates diuretic and electrolyte-mobilizing properties.
- The compound appears safe regarding cardiovascular and hemodynamic effects in the short term.
- Further research is warranted to explore the therapeutic potential of SB 7505 in conditions involving fluid and electrolyte balance.